Diag2Tec is an expert preclinical CRO devoted to hematological cancers, especially Multiple Myeloma (MM).  

We focused on in vitro Drug Testing in Human Hematological Cancer derived Cell Lines and Primary Cells from patients with various Hematologic Malignancies (Multiple Myeloma, Diffuse Large B Cells Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Mantle cell Lymphoma, Chronic Lymphoid Leukemia…).
With our 2 platforms : Drug Testing Services and ChimioFx, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and phamaceutical companies to focus their drug development on the right molecules in the right indications.

Based on our different unique models and expertise to access the Efficacy and the Mechanism of Action of various Anticancer Drugs including Targeted, Chemotherapies and Immunotherapies alone or in combination, Diag2Tec offers to pharmaceutical laboratories, biotechnology companies, CRO or academic laboratories, a large selection of preclinical services:
-	In vitro Drug Testing / Drug Screening in Hematological Cancers
-	Indentification of prognosis or predictive Biomarkers in Hematological Cancers
-	In vitro investigation of Antibody-Dependent Cellular Cytotoxicity

In addition, Diag2Tec can also offer you other customized services based on your unique needs. Contact us for more information contact@diag2tec.com


Why Choose Us?

-	Our Expertise > 30 years in the Biology of Multiple Myeloma.
-	Our Unique Collection of 40 Human Myeloma Cells Lines and Resistant Cell Lines.
-	Drug Testing in Primary Human cells from Patients with various Hematological Malignancies (with Genomic and Clinical informations available).
-	Innovative Biomathematical Models Patented for Predictive Biomarkers Identification.
-	Tailored Studies Designed to Meet your Specific Needs.
-	Short Turnaround Times for Prompt and Cost Effective Molecule Investigation.

DIAG2TEC

Org chart

Teams

Offices